A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy ...

A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...

Sarepta Therapeutics shares dropped 20% after a patient's death raises Elevidys safety concerns. Read why I am downgrading ...

Dr. Arvinder Singh Soin faced an ethical challenge when a 17-year-old girl arrived in a coma with acute liver failure.

The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...

The Company is currently analyzing the case and will update the prescribing information for Elevidys to note this development.

The grant covers the clinical and development costs of ALIVER 2.0, the randomized pivotal registration trial of Yaqrit's YAQ002. The grant is from the UK's largest funder of health R&D, the National ...

Sarepta Therapeutics Inc.'s stock tumbled 23% on Tuesday after the biotech said a patient who used its gene therapy Elevidys for the rare disease Duchenne muscular dystrophy has died of acute liver ...

Clinical trials to continue the development of a liver dialysis device to treat those with life-threatening liver disease ...

Sarepta Therapeutics said a patient taking its treatment for Duchenne muscular dystrophy has died from acute liver failure.